Radiotherapy in thyroid carcinoma

Locoregional Disease Control after External Beam Radiotherapy in Patients with Differentiated Thyroid Carcinoma and pT4 Tumor Stage

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN27923044

Enrollment

Registered

2018-01-12

Start date

2013-01-01

Completion date

Unknown

Last updated

2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Differentiated thyroid carcinoma - pT4 tumor stage Cancer Differentiated thyroid carcinoma - pT4 tumor stage

Interventions

All 91 patients included in this report had EBRT to the neck and superior mediastinum. Six patients were treated preoperatively with EBRT, four of them with concomitant chemotherapy and two with EBRT

dose from the anterior field was 1.2 Gray (Gy) and from posterior field 0.6 Gy per fraction, 5 fractions per week. The apices of the lungs were shielded

after the received dose of 39.6 Gy. The spinal cord was also shielded from the posterior field, so the dose to the spinal cord was kept bellow 45 Gy. The prescribed dose to the midplane in vast majori

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Differentiated thyroid carcinoma -pT4 tumor stage 2. Males or females older than 18 years of age;Inclusion criteria: 1. Differentiated thyroid carcinoma -pT4 tumor stage 2. Males or females older than 18 years of age

Exclusion criteria

Exclusion criteria: Younger than 18 years of age.;Exclusion criteria: Younger than 18 years of age.

Design outcomes

Primary

Measure	Time frame
Locoregional control rate was calculated by reviewing patient charts at five and ten years after external beam radiotherapy.;Locoregional control rate was calculated by reviewing patient charts at five and ten years after external beam radiotherapy.	—

Secondary

Measure	Time frame
1. Cause-specific survival was calculated using survival curves from patient charts at five and ten years after initial therapy 2. Overall survival was calculated using survival curves from patient charts at five and ten years after initial therapy ;1. Cause-specific survival was calculated using survival curves from patient charts at five and ten years after initial therapy 2. Overall survival was calculated using survival curves from patient charts at five and ten years after initial therapy	—

Measure

Time frame

1. Cause-specific survival was calculated using survival curves from patient charts at five and ten years after initial therapy 2. Overall survival was calculated using survival curves from patient charts at five and ten years after initial therapy ;1. Cause-specific survival was calculated using survival curves from patient charts at five and ten years after initial therapy 2. Overall survival was calculated using survival curves from patient charts at five and ten years after initial therapy

—

Countries

Slovenia

Contacts

Public Contact; ;

;

;;

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026